Corvus pharmaceuticals, inc. (CRVS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-47,964

-46,672

-46,134

-45,628

-44,281

-46,939

-48,359

-50,578

-53,928

-55,663

0

0

0

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-35,769

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

741

743

738

780

814

847

886

869

857

842

0

0

0

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

253

-

0

0

0

Accretion related to marketable securities

-538

-644

-736

-760

-734

-608

-455

-314

-220

-195

-48

225

524

648

0

0

0

-

-

-

-

Stock-based compensation

7,240

7,348

7,405

7,450

7,287

7,135

7,069

6,776

6,562

6,229

5,537

5,300

4,855

3,828

3,067

1,925

867

428

0

0

0

Change in fair value of convertible preferred stock liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,600

0

0

0

Other

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid and other current assets

-61

370

-476

117

-35

-187

747

-131

160

44

228

-22

-700

-290

-12

978

1,414

1,265

0

0

0

Operating lease right-of-use asset

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

50

50

-679

-549

-406

0

0

0

-

-

-

-

869

0

0

0

-

0

0

0

Accounts payable

1,092

450

25

383

-1,235

-1,456

-1,727

-1,967

1,040

1,554

1,099

2,711

1,270

518

1,928

1,069

1,018

1,240

0

0

0

Accrued and other liabilities

1,846

2,030

918

-258

-1,341

-458

-521

2,164

1,975

1,499

3,381

3,244

3,317

2,814

2,884

1,782

1,761

1,218

0

0

0

Operating lease liability

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-434

-180

-159

6

695

0

0

0

-

-

-

-

Net cash used in operating activities

-37,684

-37,321

-37,068

-37,258

-38,933

-40,988

-43,710

-43,687

-44,509

-46,212

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-14,640

-

0

0

0

Cash flows from investing activities
Purchases of marketable securities

120,094

138,586

146,929

126,908

175,967

161,861

143,041

140,692

86,094

88,309

0

0

0

-

-

-

-

-

-

-

-

Sales of marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Maturities of marketable securities

141,277

141,866

152,278

166,248

151,289

132,024

117,200

112,080

156,524

173,401

248,300

219,600

217,025

213,725

0

0

0

-

-

-

-

Purchases of property and equipment

-

25

155

311

365

355

212

94

161

266

887

944

1,696

2,199

2,450

2,357

2,037

1,747

0

0

0

Net cash provided by investing activities

22,183

3,255

5,194

39,029

-25,043

-30,192

-26,053

-28,706

70,269

84,826

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-150,455

-

0

0

0

Cash flows from financing activities
Proceeds from issuance of common stock, net (includes $30,850 in aggregate gross proceeds from related parties for the year ended December 31, 2018)

-

-

-

-

-

64,877

0

0

0

-

-

-

-

71,354

0

0

0

-

-

-

-

Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

95,569

0

0

0

Proceeds from exercise of common stock options

-

24

194

344

387

393

818

778

730

731

0

0

0

-

-

-

-

108

0

0

0

Net cash provided by financing activities

-

24

194

344

387

65,270

66,406

66,366

66,318

1,442

0

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-15,478

-34,042

-31,680

2,115

-63,589

-5,910

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

155,254

-

0

0

0

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

6,422

-

-74,023

1,691

-9,841

-8,412

0

0

0

Supplemental disclosures of cash flow information
Purchases of property and equipment incurred but not paid

-

-

-

-

0

-

-

-

-

-

-

-

-69

84

250

288

425

286

0

0

0

IPO costs incurred but not paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Convertible preferred stock liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0